Fulgent Genetics (STU:7F0) Cyclically Adjusted Revenue per Share: €10.53 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7F0 Fulgent Genetics Inc STU:7F0
72 GF Score
Price €17.20
GF Value €20.97
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Fulgent Genetics Cyclically Adjusted Revenue per Share?

Fulgent Genetics STU:7F0 -1.71% 72 Cyclically Adjusted Revenue per Share is €10.53 as of Mar. 2026. GuruFocus rates STU:7F0 with a GF Score™ of 72/100 and a GF Value™ of €20.97 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Fulgent Genetics's adjusted revenue per share for the three months ended in Mar. 2026 was €1.993. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €10.53 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Fulgent Genetics's average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-26), Fulgent Genetics's current stock price is €17.20. Fulgent Genetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €10.53. Fulgent Genetics's Cyclically Adjusted PS Ratio of today is 1.63.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Fulgent Genetics was 2.59. The lowest was 1.16. And the median was 1.81.


Fulgent Genetics  (STU:7F0) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Fulgent Genetics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.20/10.53
=1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Fulgent Genetics was 2.59. The lowest was 1.16. And the median was 1.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Fulgent Genetics Cyclically Adjusted Revenue per Share Related Terms


Fulgent Genetics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Fulgent Genetics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics Cyclically Adjusted Revenue per Share Chart

Fulgent Genetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 10.06

Fulgent Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.46 9.47 9.69 10.06 10.53

STU:7F0 vs MYGN, CSTL, BDSX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Fulgent Genetics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Cyclically Adjusted PS Ratio falls into.


STU:7F0
72GF Score
Fulgent Genetics Inc STU:7F0
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fulgent Genetics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fulgent Genetics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.993/330.2130*330.2130
=1.993

Current CPI (Mar. 2026) = 330.2130.

Fulgent Genetics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.203 241.018 0.278
201609 0.348 241.428 0.476
201612 0.318 241.432 0.435
201703 0.273 243.801 0.370
201706 0.233 244.955 0.314
201709 0.213 246.819 0.285
201712 0.203 246.524 0.272
201803 0.211 249.554 0.279
201806 0.258 251.989 0.338
201809 0.268 252.439 0.351
201812 0.275 251.233 0.361
201903 0.261 254.202 0.339
201906 0.392 256.143 0.505
201909 0.483 256.759 0.621
201912 0.382 256.974 0.491
202003 0.325 258.115 0.416
202006 0.669 257.797 0.857
202009 3.669 260.280 4.655
202012 9.041 260.474 11.462
202103 9.812 264.877 12.232
202106 4.136 271.696 5.027
202109 6.214 274.310 7.480
202112 7.142 278.802 8.459
202203 9.309 287.504 10.692
202206 3.802 296.311 4.237
202209 3.457 296.808 3.846
202212 2.093 296.797 2.329
202303 2.092 301.836 2.289
202306 2.101 305.109 2.274
202309 2.644 307.789 2.837
202312 2.172 306.746 2.338
202403 1.993 312.332 2.107
202406 2.192 314.175 2.304
202409 2.125 315.301 2.226
202412 2.374 315.605 2.484
202503 2.204 319.799 2.276
202506 2.322 322.561 2.377
202509 2.329 324.800 2.368
202512 2.297 324.054 2.341
202603 1.993 330.213 1.993

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €10.53 mean?
Fulgent Genetics (STU:7F0) has a Cyclically Adjusted Revenue per Share of €10.53 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fulgent Genetics and its competitors.
Is Fulgent Genetics' Cyclically Adjusted Revenue per Share too high?
Fulgent Genetics' current Cyclically Adjusted Revenue per Share is €10.53. Overall, Fulgent Genetics has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Cyclically Adjusted Revenue per Share compare to MYGN and CSTL?
Fulgent Genetics' Cyclically Adjusted Revenue per Share of €10.53 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current Cyclically Adjusted Revenue per Share is €10.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (STU:7F0) is currently considered Modestly Undervalued. The stock's GF Value™ is €20.97, compared to a current price of €17.20 — trading 18% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €10.53. Fulgent Genetics' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Fulgent Genetics (STU:7F0), the current Cyclically Adjusted Revenue per Share is €10.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fulgent Genetics (STU:7F0) Overvalued in 2026?

Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued. The current stock price of €17.20 is trading 18% below its estimated GF Value™ of €20.97. GuruFocus considers Fulgent Genetics to be Modestly Undervalued.

Key valuation signals for STU:7F0:

  • Cyclically Adjusted Revenue per Share: €10.53
  • GF Value™: €20.97 vs. price of €17.20 (18% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the STU:7F0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fulgent Genetics Business Description

Other Exchanges FLGT:USAFLGT:Mexico
Address 4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
72GF Score

Get the complete analysis for STU:7F0

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.20
Price
€20.97
GF Value